These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3005187)

  • 1. Differential effects of dPTyr(Me)AVP, a vasopressin antagonist, upon foot shock analgesia.
    Kordower JH; Bodnar RJ
    Int J Neurosci; 1985 Dec; 28(3-4):269-78. PubMed ID: 3005187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin analgesia: specificity of action and non-opioid effects.
    Kordower JH; Bodnar RJ
    Peptides; 1984; 5(4):747-56. PubMed ID: 6494025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
    De Wied D; Gaffori O; Van Ree JM; De Jong W
    Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
    Ferris CF; Singer EA; Meenan DM; Albers HE
    Eur J Pharmacol; 1988 Sep; 154(2):153-9. PubMed ID: 2976377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats.
    Koob GF; Le Moal M; Gaffori O; Manning M; Sawyer WH; Rivier J; Bloom FE
    Regul Pept; 1981 Jun; 2(3):153-63. PubMed ID: 7255768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate behavioral effects of interleukin-1 in rat.
    Bluthé RM; Dantzer R
    Brain Res Bull; 1992 Dec; 29(6):897-900. PubMed ID: 1473021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate social recognition in rat.
    Bluthé RM; Dantzer R
    Brain Res; 1992 Feb; 572(1-2):261-4. PubMed ID: 1611520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A V1 vasopressin receptor antagonist has nonspecific neurodepressant actions in the spinal cord.
    Porter JP; Brody MJ
    Neuroendocrinology; 1986; 43(1):75-8. PubMed ID: 3012394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP].
    LeBrun CJ; Rigter H; Martinez JL; Koob GF; Le Moal M; Bloom FE
    Life Sci; 1984 Oct; 35(14):1505-12. PubMed ID: 6482669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central and systemic effects of a vasopressin V1 antagonist on MAP recovery after haemorrhage in rats.
    Johnson JV; Bennett GW; Hatton R
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):405-12. PubMed ID: 2465440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central injections of arginine vasopressin prolong extinction of active avoidance.
    Koob GF; Dantzer R; Bluthé RM; Lebrun C; Bloom FE; Le Moal M
    Peptides; 1986; 7(2):213-8. PubMed ID: 3737445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of aversive stimulus properties of vasopressin.
    Bluthé RM; Dantzer R; Mormède P; Le Moal M
    Psychopharmacology (Berl); 1985; 87(2):238-41. PubMed ID: 3931152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular effects of arginine vasopressin during fluid deprivation in the rat.
    Aisenbrey GA; Handelman WA; Arnold P; Manning M; Schrier RW
    J Clin Invest; 1981 Apr; 67(4):961-8. PubMed ID: 7204578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vasopressin receptor antagonist dPTyr (Me) AVP does not prevent stress-induced ACTH and corticosterone release.
    Mormède P
    Nature; 1983 Mar 24-30; 302(5906):345-6. PubMed ID: 6300679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of vasopressin analgesia.
    Berkowitz BA; Sherman S
    J Pharmacol Exp Ther; 1982 Feb; 220(2):329-34. PubMed ID: 7057394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal vasopressin antagonist treatment facilitates adult copulatory behavior in female rats and increases hypothalamic vasopressin content.
    Meyerson BJ; Höglund U; Johansson C; Blomqvist A; Ericson H
    Brain Res; 1988 Nov; 473(2):344-51. PubMed ID: 3233496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of vasopressin analgesia in rats treated neonatally with monosodium glutamate.
    Bodnar RJ; Truesdell LS; Nilaver G
    Peptides; 1985; 6(4):621-6. PubMed ID: 4070021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N alpha-acetyl-[Arg8]vasopressin antagonizes the behavioral effect of [Cyt6]vasopressin-(5-9), but not of vasopressin.
    Kovács GL; Liu B; Burbach JP; Van Ree JM; De Wied D
    Eur J Pharmacol; 1989 Feb; 161(1):27-35. PubMed ID: 2721547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.